Myelodysplastic syndromes (MDSs) comprise a heterogeneous group of disorders. Recently, the WHO (World Health Organization) defined several new categories also separating chronic myelomonocytic leukemia (CMML)-1 from CMML-2 according to blast percentage. 1 In addition to blast percentage, a lower hemoglobin level, elevated lactate dehydrogenase (LDH) and lymphocyte count as well as male gender have been shown to be associated with bad outcome, whereas karyotype has not consistently shown to yield additional prognostic information. 2 Irrespective of new promising therapeutic agents, the outcome is mostly unsatisfactory and allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative option. 3, 4 Recently, List et al. 5 described meaningful responses in patients with low-risk MDS and a deletion of the long arm of chromosome 5 in those receiving lenalidomide (Revlimid). The same group also reported a patient with del(5q) acute myeloid leukemia (AML), clinically presenting with pancytopenia, responding to the compound. 6 We describe here a 66-year-old patient with 'proliferativetype' CMML-2 and single del(5q)(q31) achieving cytoreduction together with blast clearance owing to single treatment with lenalidomide. Immediately after lenalidomide-based 'induction' therapy, an allogeneic HSCT was successfully performed. The patient was initially diagnosed in April 2004 with MDS refractory anemia according to French-American-British (FAB) classification. At this time, the patient had moderate leukopenia and normal platelet counts, while cytogenetics did not reveal any abnormality. Frequency of red blood cell (RBC) transfusions (2 units) was at intervals of every 3 weeks, and in January 2006 the patient was put on deferasirox (Exjade) because of iron overload. One year later, RBC transfusion frequency worsened to 2 U every week and at the same time, the patient developed peripheral leukocytosis with monocytosis as well as thrombocytopenia. Bone marrow aspiration revealed CMML-1 with 7% blasts (5% peripheral blasts), while metaphase cytogenetics ( Figure 1a ) displayed single del(5q)(q31), which in general is rather uncommon in CMML. Interestingly, additional fluorescence in situ hybridization analysis demonstrated that this deletion did not involve EGR1 (5q31), but occurred distal to the locus, resulting in loss of the CSF1R (5q33) gene (Figure 1b) . In 5q-syndrome, the critical region of gene loss has been defined as a region at 5q31-q32 flanked by D5S413 and the GLRA1 gene. 7 This region is distinct from and distal to a 1.5 Mb region at 5q31.1 flanked by the genes IL-9 and EGR-1 and normally deleted in AML and other forms of MDS involving 5q deletions. This separation possibly implies that a different gene or group of genes contributes to the pathogenesis of these different myeloid disorders. Whether there is an influence of the type of breakpoint on the response on lenalidomide is currently unknown.
In the subsequent clinical course (Figure 2 ), peripheral blasts increased to 14% and the patient received lenalidomide at a dose of 25 mg/day for 14 days after having provided written informed consent. As a result, leukocytosis dramatically decreased from 53 to 3 Gpt/l (gigapartikel pro liter) accompanied by a normalization of LDH level. Most strikingly, the percentage of peripheral blasts decreased to 1% while platelets finally recovered to normal levels. Meanwhile, a human leukocyte antigen-identical unrelated donor had been identified. Therefore, the patient received standard conditioning with busulfan and cyclophosphamide followed by the infusion of peripheral blood stem cells. The patient engrafted and developed acute GVHD grade II of the skin. He went into complete remission, and is currently alive and well. Metaphase cytogenetic analysis (a) of this chronic myelomonocytic leukemia (CMML)-2 patient revealed del(5)(q31) in 20 out of 22 metaphases. As determined by additional fluorescence in situ hybridization analysis, the breakpoint did not involve EGR1 (5q31), but CSF1R (5q33). As shown in (b), the red signal (CSF1R-specific DNA probe directly labeled with PlatinumBright550; Poseidon, Amsterdam, Netherlands, Germany) is visible only once, whereas the green signal (EGR1-specific DNA probe labeled with PlatinumBright495; Poseidon, Germany) is not deleted.
This case clearly suggests a role of lenalidomide not only in low-risk del(5q) MDS, but also in proliferative myeloid disorders. It also points out that the type of breakpoint on chromosome 5 influences the phenotype of the disease. 8 In AML, del(5q) abnormality is mostly associated with bad response to conventional chemotherapy, which often prohibits an allogeneic HSCT as the only curative option or leads to failure of the procedure owing to early relapse. This is also because del(5q) is frequently found within a complex karyotype. Nevertheless, lenalidomide has been shown to achieve cytogenetic responses irrespective of additional aberrations. 5 Given the obvious action of lenalidomide in the clinical heterogeneous group of del(5q) diseases, there is a rationale to incorporate this compound also into cytoreductive strategies of proliferative myeloid disorders to obtain remission and improve patient outcome. In these patients, possibly higher doses compared to those conventionally used in MDS patients are needed to induce substantial and quick responses. Finally, given our observations, one might even consider prophylactic maintenance therapy in del(5q) MDS or AML after allogeneic HSCT to treat minimal residual disease and prevent imminent relapse. Clinical course of the chronic myelomonocytic leukemia (CMML)-2 patient before, during and after 14 days lenalidomide (Revlimid) treatment. Shown are peripheral blast count in %, lactate dehydrogenase (LDH) in mmol/l, white blood cell (WBC) and platelet count (PLT) in Gpt/l (gigapartikel pro liter).
